The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...

DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...

SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...

SÖDERTÄLJE, Sweden I6, 2024 I Anocca AB, a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, announces the ...

SINGAPORE I5, 2024 I SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for ...

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S.

BALDWIN PARK, CA, USA I2, 2024 I StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and ...

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right ...

YONGIN, South Korea I November 25, 2024 I GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational ...

WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...

– Interim results indicate cognitive improvement in the active treatment group compared to placebo ...